Search Results - "Markmann, S"

TRPML1 activation ameliorates lysosomal phenotypes in CLN3 deficient retinal pigment epithelial cells by Wünkhaus, D., Tang, R., Nyame, K., Laqtom, N. N., Schweizer, M., Scotto Rosato, A., Krogsæter, E. K., Wollnik, C., Abu-Remaileh, M., Grimm, C., Hermey, G., Kuhn, R., Gruber-Schoffnegger, D., Markmann, S.

“…Mutations in the lysosomal membrane protein CLN3 cause Juvenile Neuronal Ceroid Lipofuscinosis (JNCL). Activation of the lysosomal ion channel TRPML1 has…”
Get full text

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use by Eiermann, W., Rezai, M., Kümmel, S., Kühn, T., Warm, M., Friedrichs, K., Schneeweiss, A., Markmann, S., Eggemann, H., Hilfrich, J., Jackisch, C., Witzel, I., Eidtmann, H., Bachinger, A., Hell, S., Blohmer, J.

“…We carried out a prospective clinical study to evaluate the impact of the Recurrence Score (RS) on treatment decisions in early breast cancer (EBC). A total of…”
Get full text

Toward a Flexible Variable Stiffness Endoport for Single-Site Partial Nephrectomy by Amanov, E., Nguyen, T.-D., Markmann, S., Imkamp, F., Burgner-Kahrs, J.

“…Laparoscopic partial nephrectomy for localized renal tumors is an upcoming standard minimally invasive surgical procedure. However, a single-site laparoscopic…”
Get full text

Lysosomal dysfunction causes neurodegeneration in mucolipidosis II 'knock-in' mice by KOLLMANN, K, DAMME, M, KÄKELÄ, R, WALKLEY, S. U, BRAULKE, T, MARKMANN, S, MORELLE, W, SCHWEIZER, M, HERMANS-BORGMEYER, I, RÖCHERT, A. K, POHL, S, LÜBKE, T, MICHALSKI, J.-C

“…Mucolipidosis II is a neurometabolic lysosomal trafficking disorder of infancy caused by loss of mannose 6-phosphate targeting signals on lysosomal proteins,…”
Get full text

Severe acute motor neuropathy after treatment with triple tyrosine kinase inhibitor BIBF 1120 (Nintedanib) by Patejdl, R, Markmann, S, Benecke, R, Wittstock, M

“…1 Introduction The implementation of new monoclonal antibodies in treatment algorithms for malignant diseases offers the possibility of powerful and targeted…”
Get full text

Adjuvant sequential chemoradiation therapy in high-risk endometrial cancer: results of a prospective, multicenter phase-II study of the NOGGO (North-Eastern German Society of Gynaecological Oncology) by Mustea, A., Koensgen, D., Belau, A., Sehouli, J., Lichtenegger, W., Schneidewind, L., Sommer, H., Markmann, S., Scharf, J. P., Ehmke, M., Ledwon, P., Braicu, I., Zygmunt, M., Koehler, G.

“…Purpose The management of high-risk endometrial cancer (HREC) remains controversial. We conducted a prospective multicenter phase-II clinical trial to evaluate…”
Get full text

Rotational Fourier-Transform Mid-IR Spectroscopy with a Quantum Cascade Laser Frequency Comb by Markmann, S., Franckie, M., Bertrand, M., Shahmohammadi, M., Forrer, A., Jouy, P., Beck, M., Faist, J., Scalari, G.

“…Real-time spectroscopy with simultaneous high speed, high spectral resolution, and broad bandwidth is of vital importance for studying non-repetitive reactions…”
Get full text

Light-matter interaction with a Single Terahertz meta-atom by Rajabali, S., Markmann, S., Jochl, E., Beck, M., Lehner, C. A., Wegscheider, W., Faist, J., Scalari, G.

“…In this work, by combining an asymmetric Silicon immersion lens configuration and a complementary resonator design, far-field transmission measurement of a…”
Get full text

Unilateral ovarian agenesis: report of three cases and review of the literature by Mylonas, I, Hansch, S, Markmann, S, Bolz, M, Friese, K

“…Unilateral ovarian agenesis is a rare event and only a few case have been reported. We present three additional cases, where patients presented with diffuse…”
Get full text

2D - THz-Spectroscopy on a Quantum Cascade Structure by Markmann, S., Franckie, M., Pal, S., Fiebig, M., Stark, D., Beck, M., Scalari, G., Faist, J.

“…We use two-dimensional (2D) THz-spectroscopy to study the \chi^{(3)} non-linearities originating from four-wave mixing (FWM) in a quantum cascade structure…”
Get full text

8002 What is the best schedule of Topotecan? – weekly versus routine 5-day schedule in patients with platinum-resistant ovarian cancer – a randomized, multicenter trial of the North-Eastern German Society of Gynaecological Oncology (TOWER) by Sehouli, J, Oskay-Özcelik, G, Stengel, D, Harter, P, Kurzeder, C, Belau, A, Markmann, S, Lorenz, R, Mueller, L, Lichtenegger, W

Get full text

Strong coupling of intersubband resonance in a single triangular well to a THz metamaterial by Pal, S., Nongt, H., Markmann, S., Kukharchyk, N., Valentin, S. R., Scholz, S., Ludwig, A., Bock, C., Kunze, U., Wieck, A. D., Jukam, N.

“…We investigate the strong light-matter interactions of intersubband resonances (ISRs) in a triangular quantum well to a THz metamaterial. The large tuning…”
Get full text

S4-3: Prospective Comparison of Risk Assessment Tools in Early Breast Cancer (Recurrence Score, uPA/PAI-1, Central Grade, and Luminal Subtypes): Final Correlation Analysis from the Phase III WSG-Plan B Trial by Gluz, O, Kreipe, H, Degenhardt, T, Kates, R, Christgen, M, Liedtke, C, Shak, S, Clemens, M, Markmann, S, Uleer, C, Augustin, D, Thomssen, C, Nitz, U, Harbeck, N

“…Abstract Background: Both the Recurrence Score® (RS) multi-gene assay and invasion factors uPA/PAI-1 are recommended by guidelines (ASCO, AGO) for decision…”
Get full text

Abstract P2-10-08: Prospective comparison of Recurrence Score and different definitions of luminal subtypes by central pathology assessment of single markers in early breast cancer: results from the phase III WSG-planB Trial by Gluz, O, Kreipe, HH, Kates, RE, Christgen, M, Liedtke, C, Shak, S, Clemens, M, Salem, M, Liedtke, B, Aktas, B, Markmann, S, Uleer, C, Augustin, D, Thomssen, C, Nitz, U, Harbeck, N

“…Abstract Background: Routine use of multigene RT-PCR based assays as Recurrence Score (RS) vs. single markers (grade, uPA/PAI-1, HR, HER2, Ki-67) is…”
Get full text

How important is the axillary nodal status for adjuvant treatment decisions at a breast cancer multidisciplinary tumor board? A survival analysis by Reimer, T., Fietkau, R., Markmann, S., Stachs, A., Gerber, B.

“…Abstract only 11041 Background: Postoperative tumor board recommendations for breast cancer are mainly based on patient characteristics and tumor parameters…”
Get full text

P2-12-26: Impact of the Recurrence Score on Adjuvant Decision-Making in ER-Positive Early Breast Cancer – Results of a Large Prospective Multicentre Decision Impact Study in Node Negative and Node Positive Disease by Rezai, M, Eiermann, W, Kümmel, S, Kühn, T, Warm, M, Friedrichs, K, Schneeweiss, A, Markmann, S, Eggemann, H, Hilfrich, J, Jackisch, C, Witzel, I, Eidtmann, H, Kaufmann, M, Blohmer, JU

“…Abstract Background Oncotype DX® has become part of clinical routine in the diagnosis and decision-making progress in early breast cancer (EBC). Prospective…”
Get full text

Adjuvant sequential chemo-radiation therapy in high-risk endometrial cancer: Results of a prospective, multicenter phase II study of the NOGGO by Koensgen, D., Belau, A., Sehouli, J., Sommer, H. L., Bartz, K., Markmann, S., Schneidewind, L., Scharf, J. P., Ehmke, M., Stengel, D., Ledwon, P., Guba, H., Zygmunt, M., Koehler, G., Mustea, A.

“…Abstract only…”
Get full text

WSG PLAN B trial: Evaluating efficacy of anthracycline-free chemotherapy in primary HER2-negative breast cancer after molecular-based risk assessment according to Oncotype DX and uPA/PAI-1 by Gluz, O., Liedtke, C., Markmann, S., Henschen, S., Clemens, M. R., Salem, M., Thomssen, C., Kreipe, H., Harbeck, N., Nitz, U.

“…Abstract only…”
Get full text

Abstract P3-10-12: Pilot Phase of the Randomized PlanB Trial: Prospective Comparison of Molecular Classification, Oncotype DX® and Clinical-Pathological Characteristics in Hormone-Receptor (HR) Positive Primary Breast Cancer by Gluz, O, Kreipe, H, Christgen, M, Salem, M, Clemens, M, Markmann, S, Liedtke, B, Barinoff, J, Aktas, B, Henschen, S, Lübbe, K, Shak, S, Baehner, R, Liedtke, C, Nitz, U, Harbeck, N

“…Abstract Background: Despite progress in adjuvant breast cancer (BC) treatment, overtreatment due to decisions based on conventional prognostic factors (lymph…”
Get full text

Topotecan weekly versus routine 5-day schedule in patients with platinum-resistant ovarian cancer (TOWER): A randomized, multicenter trial of the North-Eastern German Society of Gynecological Oncology (NOGGO) by Sehouli, J., Oskay-Oezcelik, G., Stengel, D., Harter, P., Kurzeder, C., Belau, A., Markmann, S., Lorenz, R., Mueller, L., Lichtenegger, W.

“…Abstract only 5553 Background: In women with platinum-resistant recurrent ovarian cancer, weekly administration of topotecan (Tw) may be equally effective, but…”
Get full text